Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.63 |
| ▸ | PI4KA | P42356 | 4/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510391 | 0.78 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL17900222 | 0.75 | HSP90AA1 (0.68) | ADORA2AADORA1ADORA2BADORA3PI4KB | |
| SCHEMBL4054756 | 0.72 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL17897955 | 0.71 | HSP90AA1 (0.61) | ADORA2AADORA1ADORA2BADORA3PI4KB | |
| SCHEMBL22381523 | 0.70 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL22571151 | 0.70 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL31061588 | 0.70 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3HSP90B1 | |
| SCHEMBL8046656 | 0.68 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL8039378 | 0.68 | ADORA2A (0.47) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL13977903 | 0.68 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADORA3PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512163-B2 | Compositions and methods for conjugating oligonucleotides | AGILENT TECHNOLOGIES, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150133631-A1 | Compositions and Methods for Conjugating Oligonucleotides | AGILENT TECHNOLOGIES, INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133631-A1 | Compositions and Methods for Conjugating Oligonucleotides | DCLRE1A, NR0B1, NR0B2 | ADORA2A 1761/4885ADORA1 1116/4885ADORA2B 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.